← Browse by Condition
Medical Condition

small cell lung carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for small cell lung carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — small cell lung carcinoma Clinical Trials

How many clinical trials are currently recruiting for small cell lung carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for small cell lung carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for small cell lung carcinoma?
small cell lung carcinoma research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a small cell lung carcinoma clinical trial?
Eligibility criteria for small cell lung carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
University Hospital, Essen 1 trial
West China Hospital 1 trial
Nanfang Hospital, Southern Medical University 1 trial

Recruiting Clinical Trials

NCT06247163
Recruiting
PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
Enrollment
30 pts
Location
Germany
Sponsor
University Hospital, Essen
View Trial →
NCT07509333
Recruiting
MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients
Enrollment
2,000 pts
Location
China
Sponsor
West China Hospital
View Trial →
NCT06177925 Phase 2
Recruiting
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Enrollment
62 pts
Location
China
Sponsor
Nanfang Hospital, Southern Med...
View Trial →

Related Conditions

lung neoplasms (2) carcinoma non small cell lung (1) elderly (1) respiratory tract neoplasms (1) thoracic neoplasms (1) neoplasms by site (1) neoplasms (1) lung diseases (1) respiratory tract diseases (1) carcinoma bronchogenic (1) bronchial neoplasms (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology